476 results on '"Stilgenbauer, Stephan"'
Search Results
2. Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation
3. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial
4. T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia
5. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial
6. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies
7. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
8. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
9. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia
10. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
11. Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis
12. Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamics
13. Profile of the multicenter cohort of the German Cancer Consortium’s Clinical Communication Platform
14. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study
15. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome
16. Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL
17. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut
18. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
19. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations
20. Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia
21. Molecular map of chronic lymphocytic leukemia and its impact on outcome
22. The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
23. Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
24. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial
25. The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia
26. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
27. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients
28. Proteogenomics refines the molecular classification of chronic lymphocytic leukemia
29. Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape
30. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia
31. Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia
32. KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials
33. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia
34. Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
35. Fludarabine, cyclophosphamide, and rituximab as first‐line treatment in patients with chronic lymphocytic leukemia: A long‐term analysis of the German CLL Study Group (GCLLSG) registry.
36. Impairment of α-tubulin and F-actin interactions of GJB3 induces aneuploidy in urothelial cells and promotes bladder cancer cell invasion.
37. EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia
38. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials
39. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial
40. IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling
41. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia
42. Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas
43. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL
44. U-RT1 – A new model for Richter transformation
45. Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy
46. Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2‐BCG): Final analysis of a multicenter, open‐label phase‐II‐trial.
47. Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
48. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
49. Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia
50. Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.